OBJECTIVE： To investigate the clinical efficacy and safety of alprostadil in the treatment of heart failure in patients with normal left ventricular ejection fraction （LVEF）. METHODS： 120 patients diagnosed as heart farlture with normal LVEF were divided into observation group and control group by radom number table method， with 60 cases in each group.  Control group was given symptomatic treatment； observation group was additionally treated with Alprostadil dried emulsion for injection 10 μg， bid， on the basis of control group. Both groups received treatment for 5 d. The cardiac function indexes， serum inflammatory factors and oxidative stress indexes were observed in 2 groups before and after treatment， and the occurrence of ADR was compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in cardiac function indexes， serum inflammatory factors and oxidative stress indexes between 2 groups （P＞0.05）. After treatment， above indexes of 2 groups were all improved significantly， and the observation group was significantly better than the control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Alprostadil can improve cardiac function of patients with heart failure of normal LVEF， improve serum inflammatory factors and oxidative stress level with good safety.